|
|
Speakers 
 Dr Gianni Baer,
Scientific Director,
Merck Serono
Gianni Baer graduated in Biology from the University of Lausanne, Switzerland, and then moved to the University of Wisconsin, Madison, to complete a Ph.D. After a few years spent with Roche’s Agrochemical division in Switzerland in plant biology research, he joined Serono R&D. Over the last 15 years, he held several positions in Process Development, gaining a broad expertise in the many facets of this field, from cell biology to fill and finish activities with special emphasis on purification processes and analytical methods. He recently took a new function, leading a group dedicated to the evaluation, development and implementation of new bioprocess technologies supporting the Process Development and Manufacturing functions at the Serono Biotech Center in Switzerland.
|
Dr Leigh Bowering,
Group Leader, Microbial Fermentation Research,
UCB Celltech
|
 Dr Crawford Brown,
Chief Executive Officer,
Eden Biodesign
Crawford is CEO of Eden Biodesign (contract development and manufacturing services) and leads Eden Biopharm consulting services now established one of Europe’s largest and most successful specialist biopharmaceutical technical-regulatory consultancies.
In 2004 Eden raised £5m equity capital from an investment syndicate led by Stephens Inc, the largest privately held investment banking firm outside of Wall Street. Additionally, Eden successfully won the European-wide UK government tender to lease and operate the UK National Biomanufacturing Centre a £30 million project sponsored by the North West Development Agency, the European Regional Development Fund and the UK Department of Trade and Industry.
Crawford has been involved with the Biotech sector for over 20 years having held senior positions in product development at Celltech-Medeva Pharma (Liverpool), British Biotech (Oxford) and Wellcome Biotech (Beckenham, Kent). At Medeva, as Director of Product Development, he established one of the UK’s largest product development teams that were the first in the UK to take a recombinant vaccine from the laboratory through to approval by the European Medicines Control Agency (EMEA).
Crawford qualified from Strathclyde University with a BSc in Applied Microbiology and a PhD in Chemical and Process Engineering. He is a Senior Visiting Lecturer on Modular Training for the Bioprocess Industries (MBI) course at the Advanced Centre for Biochemical Engineering. University College, London.
Crawford has completed assignments over the past five years in Denmark, Germany, Switzerland, Netherlands, Australia, India, Japan, South Korea, Taiwan and the USA. The focus of assignments is exclusively biopharmaceutical development including therapeutic and prophylactic vaccines, monoclonal antibodies, gene therapy and stem cell/tissue engineered products.
|
Dr Stephen Burton,
Chief Executive Officer,
ProMetic BioSciences Ltd
Dr. Steven J. Burton has over 22 years of experience in the development of separation processes and materials for the purification of biopharmaceuticals. He was instrumental in the development of Mimetic Ligands™, many of which are currently used as part of industrial bioseparation processes. Dr. Burton is responsible for the creation of a research and development facility at the University of Cambridge; a leading centre for the development of synthetic affinity ligand products and associated purification processes.
After first joining as Research and Development Manager in 1988, Dr. Burton was appointed to the Board of PBL in 1993. In January 1999, Dr. Burton was appointed Vice-President, Research and Development of ProMetic BioSciences Ltd and In 2003, he was promoted to Executive Vice President with responsibility for ProMetic’s Enabling Technology Business Unit.
From 1986 to 1988, Dr. Burton was a research scientist at Delta Biotechnology, Ltd. where he was responsible for the development of downstream processes for large-scale purification of recombinant protein therapeutics.
|
Dr Yin Chen,
Vice President, Research and Development,
CytoGenix
|
 Dr Christopher Dale,
Head of Microbial Technology,
Lonza
|
 Dr Jim Davies,
Biochemical Engineer,
Lonza Biologics
|
 Dr Hans de Haard,
Director of Technology Development,
Ablynx
Prior to joining Ablynx, Dr De Haard was Manager in the Functional Biomolecules group at Unilever Research Laboratories in Vlaardingen. In that position he was in charge of the research program within Unilever concerning applications of camelid single-domain antibodies for several Unilever consumer product groups. Previously he was Project Leader in Antibody Engineering at Organon. He received his PhD from the University of Maastricht and has carried-out post-doctoral research in the area of antibody engineering for diagnostic applications.
|
Dr John Dempsey,
European Technical Specialist,
Invitrogen
|
Dr Christian Frech,
Director,
University of Mannheim
|
 Uwe Gottschalk,
Vice President,
Sartorius
|
 Dr Jürgen Hubbuch,
Head, Bioseparations Group,
Research Centre Jülich
*10/90 - 01/97 Diplom Ingenieur (Chem. Ing.)
*Faculty of Chemical Engineering
University of Karlsruhe (TH), Karlsruhe, Germany
*10/93 - 10/95 Master of Philosophy (M.Phil.)
Faculty of Process Engineering
*Heriot-Watt University, Edinburgh, Scotland
*03/97 - 12/00 Doctor of Philosophy (Ph.D.)
*BioCentrum, Center for Process Biotechnology
*Technical University of Denmark, Lyngby, Denmark
*01/01 - 12/02 Group Leader - Downstream Processing
*Institute of Enzyme Technology, Prof. M.-R. Kula
*Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
*01/03 - Group Leader - Bioseparation Group
*Institute of Biotechnology 2, Prof. C. Wandrey
*Forschungszentrum Jülich GmbH, Jülich, Germany
|
 Dr Hans Huber,
Technology Agent - Biopharmacetuical Production,
Boehringer Ingelheim Austria
Hans Huber has been working as a bioprocess engineer in the Process Science Group of Boehringer Ingelheim Austria, Vienna since 1999. In his current position, he is a Technology Agent for biopharmaceutical production, in which he is responsible for innovation management and the implementation of enabling technologies. From 2002 – 2006, he was head of the Unit Microbial Fermentation Development, where he was responsible for development and scale-up of fermentation processes for recombinant proteins and plasmids. Dr. Huber holds a PhD in Biotechnology from the University of Natural Resources and Life Sciences / Vienna and did his thesis on industrial manufacturing of therapeutic plasmid DNA.
|
 Dr Lothar Jacob,
Marketing Manager Process Separations,
Merck
|
Dr Karen Jervis,
Vice President and Managing Director,
Viragen (Scotland) Limited
|
 Dr Norbert Klein,
Site Head Technical Operations,
Novartis Vaccines and Diagnostics
Norbert Klein is responsible for a site where a range of bacterial and viral vaccines including cell culture-derived influenza vaccines are manufactured. Norbert has 15 years experience in the pharmaceutical and vaccine industry. He has been in his current position since 2006. Previously he held positions as head of manufacturing and project manager at Chiron Vaccines and vaccine development manager at Hoechst and Intervet/Akzo Nobel. He began his career as a vaccine production manager at Behringwerke. Norbert holds a PhD degree from Free University of Berlin in Virology and a degree in Veterinary Medicine.
|
 Dr Hans-Peter Knopf,
Head, Protein Expression Technologies,
Novartis Pharma
Hans-Peter received his Ph.D. in Molecular and Cell Biology at the Albert-Ludwigs University of Freiburg, Germany, working in conjunction with the University Clinic and the Max-Planck Institute of Immunology. During 1994/5 he was Post Doc at the Max Planck Institute of Immunology, Freiburg, focused on the characterization of primary human monocytes and macrophages.
Hans-Peter joined Novartis AG / Biotechnology Development in 1995 as a lab head in cell and molecular biology. As he was responsible for the development of cell lines, cell banking and molecular biological analytics, he was involved in the registration procedures for biopharmaceuticals. From 1999 to 2005 he served as a group head in “Cell and Molecular Biology”, where he was responsible for the development of expression vectors and production cell lines and all cGMP related aspects. During 2005 to 2006 he served as a head of “Protein Expression Technologies”, focused on the evaluation and development of new expression technologies for glycosylated biopharmaceuticals. In 2006 he joined the management team of Biotechnology Development as a Technical Project Leader and is responsible for the mammalian cell line as well as the alternative expression platforms.
|
 Prof Massimo Morbidelli,
Head, The Morbidelli Group,
ETH Zurich
Massimo Morbidelli received his Laurea in Chemical Engineering at the Politecnico di Milano in 1977 and his PhD in Chemical Engineering at the University of Notre Dame in 1986. After his first appointments as professor at the University of Cagliari (Italy) and then at the Politecnico di Milano, he is, since 1997, Professor of Chemical Reaction Engineering at the Institute for Chemical and Bioengineering at ETH Zurich (Switzerland).
His main research interests are in Chemical Reaction Engineering, with particular emphasis on polymer reactions and reaction-separation processes based on continuous chromatography. More recently, his interest in chromatographic separations is evolved in the area of biomolecules with specific focus on therapeutic proteins and monoclonal antibodies. The general aim of his research is the development of new concepts for the down stream processing of these materials.
Massimo Morbidelli is co-author of more than 300 papers, 11 international patents and four books. He serves as a member of the Editorial Board of the Cambridge University Press Series in Chemical Engineering, as well as of several international scientific journals. He is a member of the Scientific Advisory Board of the Max-Planck Institute for Dynamics and Complex Technical Systems, Magdeburg, Germany. He is the recipient of the 2005 R.H. Wilhelm Award in Chemical Reaction Engineering of the American Institute of Chemical Engineers.
|
Andy Nixon,
Senior Director, Discovery Research,
Dyax
|
 Dr Hélène Pora,
Vaccine Application Director,
Pall Life Sciences
Dr Hélène Pora is Vaccine Application Development director with Pall LIfe Sciences , where she has the worldwide responsibility for the development of improved separation and purification solutions for the vaccine and gene therapy market. She is also heavily involved in the development of improved single use technologies and related scale-up aspects. Hélène has more than 20 years of experience working for the pharmaceutical and the separation industries, the last 15 years with Pall Corporation. She holds an Engineering Degree in Biochemistry (with Molecular Biology) from the Institut National Agronomique (France) and a PhD in Biochemistry ( on protein engineering and purification) from the University of Orsay (France). Hélène Speaks regularly at conferences about improved separation technologies for the biotechnology and biopharmaceutical industry.
|
 Dr Ranjini Ramachander,
Scientist, Global Cellular and Analytical Resources,
Amgen
Dr. Ranjini Ramachander is a Scientist in the Global Cellular and Analytical Resources at Amgen Inc in Thousand Oaks, CA. She has Ph.D in Biochemistry from the University of California at Los Angeles, and a Masters in Biotechnology from the Indian Institute of Technology, Bombay, India. At Amgen, one of Dr. Ramachander’s area of focus is on understanding the manufacturability of therapeutic antibodies as assessed by biophysical tools. She will be presenting a few representative case studies at this conference.
|
 Dr Mark Rayner,
Technology Transfer Manager,
Eden Biodesign Ltd
|
 Dr. Yoseph Shaaltiel,
E.VP, R&D,
Protalix Ltd.
|
 Dr Anthony Simula,
Head of Research and Development,
Novozymes GroPep Ltd
|
Simon Thompson,
Project Manager,
Genvax Ltd / MMI Group
|
Dr Richard Turner,
Director of Regulatory Affairs (UK,
Era Consulting Group
Dr Richard Turner is the Director of Regulatory Affairs at ERA Consulting (UK) Ltd., the UK arm of the ERA Consulting Group. Dr Turner obtained a BSc in Applied Biology from Thames Polytechnic London in 1986. In 1990 he received his PhD in Microbial Biochemistry from the University of East Anglia where he studied the structural and functional properties of proteins from microbial respiratory pathways using magnetic circular dichroism, electron paramagnetic resonance and nuclear magnetic resonance spectroscopies. Between 1991 and 1997, Dr Turner was a research scientist in the Process Development Department of Delta Biotechnology Ltd., Nottingham. Leading a team of scientists Dr Turner developed downstream processes and analytical tests for the manufacture of recombinant human serum albumin.
|
Dr Martin Wisher,
Scientific Director,
BioReliance
Martin Wisher is Scientific Director at BioReliance, a leading contract testing company that performs cell line characterisation, viral clearance, analytical chemistry and manufacturing services to the biological/biopharmaceutical industry worldwide. Martin has worked for BioReliance for over 17 years and has a total of over 21 years experience in the contract services industry. In this time he has been responsible for running routine laboratory services, developing new assays and services and Head of Quality Systems and Regulatory Affairs. As Scientific Director he spends considerable time working with clients to devise testing strategies that will meet the requirements of regulatory agencies worldwide. Martin gained his Ph.D. in membrane biochemistry from the National institute for Medical Research, London and has been involved in the development of monoclonal antibodies and recombinant vaccines.
|
|
|
|
